Complete preclinical platform for intravitreal chemotherapy drug discovery for retinoblastoma: Assessment of pharmacokinetics, toxicity and efficacy using a rabbit model

Current melphalan-based intravitreal chemotherapy regimens for retinoblastoma vitreous seeds are effective, but cause significant ocular toxicity. We describe protocols for each step of a drug discovery pipeline for preclinical development of novel drugs to maximize efficacy and minimize toxicity. T...

Full description

Bibliographic Details
Main Authors: Anthony B. Daniels, Janene M. Pierce, Sheau-chiann Chen
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:MethodsX
Subjects:
Eye
Online Access:http://www.sciencedirect.com/science/article/pii/S2215016121001515
id doaj-ef8eccb8dee742ffb0e61679faca0608
record_format Article
spelling doaj-ef8eccb8dee742ffb0e61679faca06082021-05-02T05:54:51ZengElsevierMethodsX2215-01612021-01-018101358Complete preclinical platform for intravitreal chemotherapy drug discovery for retinoblastoma: Assessment of pharmacokinetics, toxicity and efficacy using a rabbit modelAnthony B. Daniels0Janene M. Pierce1Sheau-chiann Chen2Division of Ocular Oncology and Pathology, Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, TN, United States; Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN, United States; Program in Cancer Biology, Vanderbilt University, Nashville, TN, United States; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, United States; Corresponding author.Division of Ocular Oncology and Pathology, Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, TN, United StatesVanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, United States; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United StatesCurrent melphalan-based intravitreal chemotherapy regimens for retinoblastoma vitreous seeds are effective, but cause significant ocular toxicity. We describe protocols for each step of a drug discovery pipeline for preclinical development of novel drugs to maximize efficacy and minimize toxicity. These protocols include: 1) determination of vitreous pharmacokinetics in vivo, 2) in vitro assessment of drug cytotoxicity against retinoblastoma based on empiric pharmacokinetics, 3) back-calculation of minimum injection dose to achieve therapeutic concentrations, 4) in vivo determination of maximum-tolerable intravitreal dose, using a multimodal, structural and functional toxicity-assessment platform, and 5) in vivo determination of drug efficacy using a rabbit orthotopic xenograft model of retinoblastoma vitreous seeds. We likewise describe our methodology for direct quantitation of vitreous seeds, and the statistical methodology for assessment of toxicity and efficacy in evaluating novel drugs, as well as for comparisons between drugs. • Multi-step pipeline for intravitreal chemotherapy drug discovery for retinoblastoma, using novel rabbit models. • Detailed protocols for determination of vitreous pharmacokinetics, calculation of optimal dose to inject to achieve therapeutic vitreous levels, determination of maximum tolerable dose using a novel complete toxicity-assessment platform, and in vivo efficacy against retinoblastoma using methodology to directly quantify vitreous tumor burden. • Associated statistical methodology is also presented.http://www.sciencedirect.com/science/article/pii/S2215016121001515Animal modelsChemotherapyDrug discoveryEfficacyEyeOcular tumors
collection DOAJ
language English
format Article
sources DOAJ
author Anthony B. Daniels
Janene M. Pierce
Sheau-chiann Chen
spellingShingle Anthony B. Daniels
Janene M. Pierce
Sheau-chiann Chen
Complete preclinical platform for intravitreal chemotherapy drug discovery for retinoblastoma: Assessment of pharmacokinetics, toxicity and efficacy using a rabbit model
MethodsX
Animal models
Chemotherapy
Drug discovery
Efficacy
Eye
Ocular tumors
author_facet Anthony B. Daniels
Janene M. Pierce
Sheau-chiann Chen
author_sort Anthony B. Daniels
title Complete preclinical platform for intravitreal chemotherapy drug discovery for retinoblastoma: Assessment of pharmacokinetics, toxicity and efficacy using a rabbit model
title_short Complete preclinical platform for intravitreal chemotherapy drug discovery for retinoblastoma: Assessment of pharmacokinetics, toxicity and efficacy using a rabbit model
title_full Complete preclinical platform for intravitreal chemotherapy drug discovery for retinoblastoma: Assessment of pharmacokinetics, toxicity and efficacy using a rabbit model
title_fullStr Complete preclinical platform for intravitreal chemotherapy drug discovery for retinoblastoma: Assessment of pharmacokinetics, toxicity and efficacy using a rabbit model
title_full_unstemmed Complete preclinical platform for intravitreal chemotherapy drug discovery for retinoblastoma: Assessment of pharmacokinetics, toxicity and efficacy using a rabbit model
title_sort complete preclinical platform for intravitreal chemotherapy drug discovery for retinoblastoma: assessment of pharmacokinetics, toxicity and efficacy using a rabbit model
publisher Elsevier
series MethodsX
issn 2215-0161
publishDate 2021-01-01
description Current melphalan-based intravitreal chemotherapy regimens for retinoblastoma vitreous seeds are effective, but cause significant ocular toxicity. We describe protocols for each step of a drug discovery pipeline for preclinical development of novel drugs to maximize efficacy and minimize toxicity. These protocols include: 1) determination of vitreous pharmacokinetics in vivo, 2) in vitro assessment of drug cytotoxicity against retinoblastoma based on empiric pharmacokinetics, 3) back-calculation of minimum injection dose to achieve therapeutic concentrations, 4) in vivo determination of maximum-tolerable intravitreal dose, using a multimodal, structural and functional toxicity-assessment platform, and 5) in vivo determination of drug efficacy using a rabbit orthotopic xenograft model of retinoblastoma vitreous seeds. We likewise describe our methodology for direct quantitation of vitreous seeds, and the statistical methodology for assessment of toxicity and efficacy in evaluating novel drugs, as well as for comparisons between drugs. • Multi-step pipeline for intravitreal chemotherapy drug discovery for retinoblastoma, using novel rabbit models. • Detailed protocols for determination of vitreous pharmacokinetics, calculation of optimal dose to inject to achieve therapeutic vitreous levels, determination of maximum tolerable dose using a novel complete toxicity-assessment platform, and in vivo efficacy against retinoblastoma using methodology to directly quantify vitreous tumor burden. • Associated statistical methodology is also presented.
topic Animal models
Chemotherapy
Drug discovery
Efficacy
Eye
Ocular tumors
url http://www.sciencedirect.com/science/article/pii/S2215016121001515
work_keys_str_mv AT anthonybdaniels completepreclinicalplatformforintravitrealchemotherapydrugdiscoveryforretinoblastomaassessmentofpharmacokineticstoxicityandefficacyusingarabbitmodel
AT janenempierce completepreclinicalplatformforintravitrealchemotherapydrugdiscoveryforretinoblastomaassessmentofpharmacokineticstoxicityandefficacyusingarabbitmodel
AT sheauchiannchen completepreclinicalplatformforintravitrealchemotherapydrugdiscoveryforretinoblastomaassessmentofpharmacokineticstoxicityandefficacyusingarabbitmodel
_version_ 1721494752223821824